Jurczak F, Laridon J Y, Raffaitin Ph, Pousset J P
Service de chirurgie viscérale et carcinologique, polyclinique de l'Océan, 38, rue de Pornichet, 44600 Saint-Nazaire, France.
Ann Chir. 2004 Jun;129(5):286-9. doi: 10.1016/j.anchir.2004.04.007.
The different treatments proposed for transsphincteric and suprasphincteric cryptoglandular anal fistulas are often complex and often associated with complications. After one or two stage anal fistulotomy, the risk of change in fecal continence ranks from 30% to 40%. This rate is lower (10%) with transanal advancement flap repair technique. A new therapeutic approach (fistula track closure by means of a fibrin sealant) that we have developed in our study allows to avoid classical sphincter dissection or section which could jeopardize normal sphincter function.
Over a 20 month period, 31 consecutive patients (mean age: 42; 24 males and seven females) with transsphincteric (n = 28) or suprasphincteric (n = 3) anal fistula have been included in this study and treated with injection of a fibrin sealant into fistula track. Patients were controlled during a mean follow-up of 9 month.
Fistula cure was obtained in 83.9% cases (75% after single fibrin sealant application). Success was achieved after a second application in two patients. Neither change in fecal continence nor other complication was observed during application and during follow-up period.
This technique is simple (100% feasibility) and is reproductible. Results are comparable with "classical" techniques. However, despite this surgical procedure which could be seen as simple, it requires a throrough methodology.
针对经括约肌型和括约肌上型隐窝腺性肛瘘提出的不同治疗方法通常较为复杂,且常伴有并发症。在进行一或两期肛瘘切开术后,大便失禁的风险为30%至40%。采用经肛门推进皮瓣修复技术时,该发生率较低(10%)。我们在研究中开发的一种新治疗方法(通过纤维蛋白密封剂封闭瘘管)可避免可能危及正常括约肌功能的经典括约肌解剖或切断。
在20个月期间,本研究纳入了31例连续的经括约肌型(n = 28)或括约肌上型(n = 3)肛瘘患者(平均年龄:42岁;24例男性,7例女性),并通过向瘘管内注射纤维蛋白密封剂进行治疗。在平均9个月的随访期间对患者进行了监测。
83.9%的病例实现了肛瘘治愈(单次应用纤维蛋白密封剂后为75%)。两名患者在第二次应用后取得成功。在应用过程和随访期间均未观察到大便失禁的变化或其他并发症。
该技术简单(可行性100%)且可重复。结果与“经典”技术相当。然而,尽管该手术操作看似简单,但仍需要严谨的方法。